Molecule
Risankizumab is an interleukin-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy, among other approved uses. MedsAcross supplies Risankizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
SKYRIZI is an interleukin-23 antagonist indicated for the treatment of: moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy. active psoriatic arthritis in adults and pediatric patients 6 years of age and older. moderately to severely active Crohn's disease in adults. moderately to severely active ulcerative colitis in adults.
Source: US FDA prescribing information
Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Risankizumab-rzaa inhibits the release of pro-inflammatory cytokines and chemokines.
Source: US FDA prescribing information
For the treatment of moderately to severely active Crohn’s disease and ulcerative colitis: Obtain liver enzymes and bilirubin levels prior to initiating treatment with SKYRIZI. Complete all age-appropriate vaccinations as recommended by current immunization guidelines. Recommended Dosage Moderate-to-Severe Plaque Psoriasis: Adults: 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter. Pediatric P atients 6 Years of Age and Older: Patients weighing less than 40 kg: 55 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter. Patients weighing 40 kg or greater: 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter. Active Psoriatic Arthritis: Adults: 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.
Source: US FDA prescribing information
SKYRIZI is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of the excipients.
Source: US FDA prescribing information
Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis, may occur. Infections: SKYRIZI may increase the risk of infection. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If such an infection develops, do not administer SKYRIZI until the infection resolves. Tuberculosis (TB): Consider evaluating for TB prior to initiating treatment with SKYRIZI based on clinical judgement. Hepatotoxicity: Drug-induced liver injury during induction treatment of inflammatory bowel disease has been reported. Monitor liver enzymes and bilirubin levels at baseline and, during induction, up to at least 12 weeks of treatment. Monitor thereafter according to routine patient management. Immunizations: Avoid use of live vaccines.
Source: US FDA prescribing information
The following adverse reactions are discussed in other sections of labeling: Hypersensitivity Reactions Infections Tuberculosis Hepatotoxicity Most common adverse reactions are: Plaque Psoriasis and Psoriatic Arthritis (≥ 1%): upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections. Crohn’s Disease (>3%): • Induction: upper respiratory infections, headache, and arthralgia. • Maintenance: arthralgia, abdominal pain, injection site reactions, anemia, pyrexia, back pain, arthropathy, and urinary tract infection. Ulcerative Colitis (≥3%): • Induction: arthralgia. • Maintenance: arthralgia, pyrexia, injection site reactions, and rash.
Source: US FDA prescribing information
Store in a refrigerator at 36°F to 46° F (2°C to 8°C). Do not freeze. Do not shake. Keep in the original cartons to protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
6 presentations of Risankizumab, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Skyrizi kitIntravenous Cold chain | AbbVie | US FDA | Available on request |
| Skyrizi kit Cold chain | AbbVie | US FDA | Available on request |
| Skyrizi 150 mg/1 mL injectionSubcutaneous Cold chain | AbbVie | US FDA | Available on request |
| Skyrizi 180 mg/1.2 mL injectionSubcutaneous Cold chain | AbbVie | US FDA | Available on request |
| Skyrizi 55 mg/0.37 mL injectionSubcutaneous Cold chain | AbbVie | US FDA | Available on request |
| Skyrizi 600 mg/10 mL injectionIntravenous Cold chain | AbbVie | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 6 presentations of Risankizumab and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Risankizumab, including Skyrizi.
Yes. The US FDA first approved Risankizumab on 23 April 2019, according to Drugs@FDA.
Yes. Risankizumab has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Risankizumab must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Risankizumab is classified under ATC code L04AC18 (Risankizumab).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.